There is a strong demand for a modular laboratory workflow platform from molecular diagnostics and applied testing customers worldwide, as well as for use in pharma and academia.
The growth of QIAsymphony, which offers full workflow solutions from biological sample to result, reached well more than 750 placements at the end of 2012. QIAsymphony gives customers access to a broad range of commercially available assays while also allowing them to run laboratory-developed tests (LDTs), which often account for more than half the volume of molecular testing in a typical laboratory. Additional features include continuous loading, random access, and the ability to process an almost unlimited range of sample types.
QIAsymphony is an easy-to-use modular system produced by Qiagen (Hilden, Germany), which integrates a molecular laboratory’s workflow from initial biological sample processing to final result. "We are very pleased to have exceeded our 2012 target for QIAsymphony, a breakthrough automation system that is improving laboratory workflows and accelerating the dissemination of molecular testing. We expect QIAsymphony to be a growth driver for QIAGEN over the next decade, and the strong uptake in the early years of its introduction is very positive,” said Peer M. Schatz, CEO of Qiagen N.V. “Customers in Molecular Diagnostics, Applied Testing and other types of molecular laboratories continue to respond positively to the cost-effective workflow and growing menu of test content for the QIAsymphony. We expect QIAsymphony placements to exceed 1,000 by the end of 2013 while also delivering on initiatives to expand the test menu, particularly in the United States and Europe that will further increase the use of our consumables by customers.”